← Human Trials & Peer-Reviewed Studies
The effect of leukocyte-platelet-rich fibrin on bone morphogenetic protein-2 and insulin-like growth factor-1 levels in patients with chronic periodontitis: a randomized split mouth clinical trail
Plain-language guide to PMID 30624092 (2018): randomized controlled trial study of IGF-1 LR3 in 16 patients.
Key Facts
- PMID
- 30624092
- Journal
- Growth factors (Chur, Switzerland)
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Kizildağ A et al. (4 authors)
- DOI
- 10.1080/08977194.2018.1551217
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3, published as a randomized controlled trial.
The present study evaluates the effects of leukocyte-platelet-rich fibrin (L-PRF) combined with open flap debridement (OFD) on clinical parameters and growth factors levels (GFL) in chronic periodontitis (CP) patients.
GFL in gingival crevicular fluid (GCF) were analyzed at baseline, 1 week, 2 weeks and 4 weeks after operation.
Who Took Part
The abstract describes 16 patients taking part.
This trial was registered at clinicaltrials.gov as NCT02594605. 16 patients (32 sites) with chronic periodontitis who had at least two areas of horizontal bone loss, were treated with OFD alone or L-PRF with OFD (OFD + L-PRF).
Probing depth (PD) and clinical attachment level (CAL) were measured at baseline and 6 months postoperatively.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.
What Was Measured
The present study evaluates the effects of leukocyte-platelet-rich fibrin (L-PRF) combined with open flap debridement (OFD) on clinical parameters and growth factors levels (GFL) in chronic periodontitis (CP) patients.
The subject headings attached to it are Bone Morphogenetic Protein 2, Bone Regeneration, Chronic Periodontitis, Debridement, Gingiva, Insulin-Like Growth Factor I and Platelet-Rich Fibrin.
Author keywords: BMP-2, IGF-1 and wound healing.
What This Means in Plain Language
The paper is a randomized study of IGF-1 LR3 in 16 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2018 (Growth factors (Chur, Switzerland)), a journal based in England.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.